Jose Francisco Leis MD PhD

PubMed

• Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study.
  Mazie Tsang, Paul J Hampel, Kari G Rabe, Christian Brieghel, Wei Ding
  American Journal of Hematology. 2025-06-18
• 1 citations
  Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
  Paul J Hampel, Kari G Rabe, Yucai Wang, Steven R Hwang, Saad S Kenderian
  Leukemia. 2025-02-01
• 1 citations
  Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.
  Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan O'Brien
  Blood Advances. 2025-01-14

Journal Articles

• Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
  Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology

Abstracts/Posters

• Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
  Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
  Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
  Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Management of Steroid Resistant Acute and Chronic GVHD: Are We Making Progress? 
  CIBMTR and ASBMT BMT Tandem Meeting, Salt Lake City, UT - 2/2018
• CLL: What To Do After BTK Inhibitor Therapy Fails 
  Great Debates & Updates in Hematologic Malignancies, New York, NY - 4/2018
• How I Treat Newly Diagnosed, Relapsed, and Transformed CLL Patients 
  American Society of Hematology (ASH) Meeting on Hematologic Malignancies, Chicago, IL - 9/2019
• Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 
  25th Annual North American Educational Forum on Lymphoma, Lymphoma Research Foundation - 10/25/2020
• Third-line therapy and Stem Cell Transplantation for Chronic Lymphocytic Leukemia 
  Global Virtual Patient and Caregiver Educational Forum, CLL Society - 10/12/2020
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all